| Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiosensitization. | |
| | |
MedLine Citation:
|
PMID: 19652528 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Acetyl group turnover on specific lysine epsilon-amino groups of the core chromosomal histones regulates DNA accessibility function, and the acetylating and deacetylating enzymes that govern the turnover provide important targets for the development of anti-cancer drugs. Histone deacetylase (HDAC) inhibitors have been developed and evaluated extensively in clinical trials, while the development of inhibitors of histone acetyltransferase (HAT) has proceeded more slowly. Here we have examined the cellular effects of an S-substituted coenzyme A (CoA) inhibitor of histone acetylation, consisting of spermidine (Spd) linked to the S-terminus of CoA through a thioglycolic acid linkage (adduct abbreviated as Spd-CoA), as well as the effects of a truncated Spd-CoA derivative lacking the negatively charged portion of the CoA moiety. While exposure of cancer cells to Spd-CoA has little effect on cell viability, it causes a rapid inhibition of histone acetylation that correlates with a transient arrest of DNA synthesis, a transient delay in S-phase progression, and an inhibition of nucleotide excision repair and DNA double strand break repair. These effects correlate with increased cellular sensitivity to the DNA-targeted chemotherapeutic drugs, cisplatin (Platinol()) and 5-fluorouracil, to the DNA damaging drug, camptothecin, and to UV-C irradiation. The sensitization effects of Spd-CoA are not observed in normal cells due to a barrier to uptake. The truncated Spd-CoA derivative displays similar but enhanced chemosensitization effects, suggesting that further modifications of the Spd-CoA structure could further improve potency. The results demonstrate that Spd-CoA and its truncated version are efficiently and selectively internalized into cancer cells, and suggest that the resulting inhibition of acetylation-dependent DNA repair enhances cellular sensitivity to DNA damage. These and related inhibitors of histone acetylation could therefore constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments. |
| | |
Authors:
|
Keya Bandyopadhyay; Jean-Louis Banères; Aimée Martin; Casimir Blonski; Joseph Parello; Ruth A Gjerset |
Related Documents
:
|
3005108 - Transcriptional antitermination activity of the synthetic nut elements of coliphage lam... 11739728 - P300-mediated tax transactivation from recombinant chromatin: histone tail deletion mim... 19948258 - Signalling to chromatin through post-translational modifications of hmgn. 8886008 - H1-h1 cross-linking efficiency depends on genomic dna methylation. 21445788 - Elevated mitochondrial dna copy number and pol-γ expression but decreased expression o... 7151038 - Cytologic detection of virus-specific dna by in situ hybridization in syrian hamster em... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-09-02 |
Journal Detail:
|
Title: Cell cycle (Georgetown, Tex.) Volume: 8 ISSN: 1551-4005 ISO Abbreviation: Cell Cycle Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-09-08 Completed Date: 2009-12-14 Revised Date: 2011-07-28 |
Medline Journal Info:
|
Nlm Unique ID: 101137841 Medline TA: Cell Cycle Country: United States |
Other Details:
|
Languages: eng Pagination: 2779-88 Citation Subset: IM |
Affiliation:
|
Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylation Antineoplastic Agents / chemistry, pharmacology* Cell Line, Tumor Coenzyme A / chemistry, pharmacology* DNA Repair* Histone Acetyltransferases / antagonists & inhibitors*, metabolism Histones / metabolism* Humans Lung Neoplasms / drug therapy S Phase Spermidine / analogs & derivatives*, chemistry, pharmacology* |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA111868-01/CA/NCI NIH HHS; R01 CA111868-02/CA/NCI NIH HHS; R01 CA111868-03/CA/NCI NIH HHS; R01 CA111868-04/CA/NCI NIH HHS; R01 CA111868-05/CA/NCI NIH HHS; R01 CA111868-06/CA/NCI NIH HHS; R01 CA135369-01/CA/NCI NIH HHS; R01CA111868/CA/NCI NIH HHS; R01CA135369/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/H2AFX protein, human; 0/Histones; 124-20-9/Spermidine; 85-61-0/Coenzyme A; EC 2.3.1.48/Histone Acetyltransferases |
| Comments/Corrections | |
Comment In:
|
Cell Cycle. 2009 Sep 15;8(18):2867
[PMID:
19736512
]
|
Erratum In:
|
Cell Cycle. 2010 Mar;9(5):1023 Note: Dosage error in article text |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the ...
Next Document: RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK.